Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018162722) DPP-4 INHIBITORS FOR USE IN TREATING BONE FRACTURES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/162722 International Application No.: PCT/EP2018/055931
Publication Date: 13.09.2018 International Filing Date: 09.03.2018
IPC:
A61K 31/00 (2006.01) ,A61K 31/40 (2006.01) ,A61K 31/403 (2006.01) ,A61K 31/496 (2006.01) ,A61K 31/4985 (2006.01) ,A61K 31/513 (2006.01) ,A61K 31/519 (2006.01) ,A61K 31/522 (2006.01) ,A61K 45/06 (2006.01) ,A61K 31/155 (2006.01) ,A61P 19/10 (2006.01) ,A61P 19/08 (2006.01) ,C12N 5/077 (2010.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403
condensed with carbocyclic rings, e.g. carbazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4985
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
513
having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
52
Purines, e.g. adenine
522
having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
155
Amidines (), e.g. guanidine (H2N-C(NH)-NH2), isourea (HNC(OH)NH2), isothiourea (HNC(SH)-NH2)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19
Drugs for skeletal disorders
08
for bone diseases, e.g. rachitism, Paget's disease
10
for osteoporosis
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19
Drugs for skeletal disorders
08
for bone diseases, e.g. rachitism, Paget's disease
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07
Animal cells or tissues
071
Vertebrate cells or tissues, e.g. human cells or tissues
077
Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
Applicants:
SARAIVA, Luís Miguel Rodrigues [PT/QA]; QA
DEUTSCHES INSTITUT FÜR ERNÄHRUNGSFORSCHUNG POTSDAM-REHBRÜCKE [DE/DE]; Arthur-Scheunert-Allee 114 - 116 14558 Nuthetal, DE
SIDRA MEDICAL AND RESEARCH CENTER [QA/QA]; Human Genetics Department Translational Medicine Division Out-Patient Clinic, C6-113 PO Box 26999 Doha, QA
Inventors:
SARAIVA, Luís Miguel Rodrigues; QA
SCHULZ, Tim Julius; DE
AMBROSI, Thomas Hans; US
Agent:
ZWICKER, Jörk; ZSP Patentanwälte Partnerschaftsgesellschaft mbB Hansastr. 32 80686 München, DE
Priority Data:
62/469,45309.03.2017US
Title (EN) DPP-4 INHIBITORS FOR USE IN TREATING BONE FRACTURES
(FR) INHIBITEURS DE DPP-4 À UTILISER DANS LE TRAITEMENT DE FRACTURES OSSEUSES
Abstract:
(EN) The present disclosure provides DPP-4 inhibitors for use in treating a bone fracture, for use in preventing non-union of a bone fracture or preventing healing complications following bone fracture, for use in reducing the inhibitory effects of marrow adipose tissue (MAT) on fracture healing, or for use in preventing loss of bone mineral density (BMD) in a subject in need thereof. The disclosure also provides methods of preparing cells for transplantation comprising providing a cell culture comprising osteogenic progenitor cells (OPCs) and/or mesenchymal stem cells, and contacting the cells with a DPP-4 inhibitor. The disclosure further provides methods of preparing cells for transplantation comprising providing a cell culture comprising CD45-CD31- Sca1+ CD24+ multipotent cells, and treating the cell culture to promote lineage commitment and/or differentiation into osteogenic progenitor cells (OPCs) and/or mature cells of the osteogenic lineage/bone tissues.
(FR) La présente invention concerne des inhibiteurs de DPP-4 à utiliser pour traiter une fracture osseuse, pour prévenir l'absence de consolidation d'une fracture osseuse ou pour prévenir des complications de cicatrisation à la suite d'une fracture osseuse, pour réduire des effets inhibiteurs de tissus adipeux de moelle (MAT) sur la cicatrisation d'une fracture, ou pour prévenir la perte de densité minérale osseuse (BMD) chez un patient nécessitant un tel traitement. L'invention concerne également des méthodes de préparation de cellules en vue d'une greffe qui consistent à fournir une culture cellulaire comprenant des cellules progénitrices ostéogéniques (OPC) et/ou des cellules souches mésenchymateuses, et à mettre en contact les cellules avec un inhibiteur de DPP-4. L'invention concerne en outre des méthodes de préparation de cellules en vue d'une greffe qui consistent à fournir une culture cellulaire comprenant des cellules multipotentes CD45-CD31- Sca1+ CD24+, et à traiter la culture cellulaire pour favoriser l'implication et/ou la différenciation de lignée en cellules progénitrices ostéogéniques (OPC) et/ou en cellules matures des tissus osseux/de lignée ostéogéniques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)